Understanding the interplay between the levels of airway inflammation and CFTR modulator efficacy, as illustrated in Figure 3C, will likely lead to improvements of CFTR modulator therapies and further benefit CF patients. This evidence concerns the gene CFTR and cystic fibrosis.